MELTZER LESLIE has filed 3 insider transactions across 1 company since August 2025.
Most recent transaction: a grant/award of 45220 shares of Apellis Pharmaceuticals, Inc. ($APLS) on January 28, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 28, 2026 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Common Stock | 45220 | $0.00 | 107,024.0000 | 130,067,000 | 73.17% | 0.03% |
| Aug. 26, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Common Stock | 61804 | $0.00 | 61,804.0000 | 123,905,000 | 9999.99% | 0.05% |
| Aug. 26, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | MELTZER LESLIE | Chief Research and Development | A | Stock Option (Right to Buy) | 92592 | $0.00 | 92,592.0000 | 123,905,000 | 9999.99% | 0.07% |